# Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

> **NCT00290017** · PHASE3 · TERMINATED · sponsor: **Point Therapeutics** · enrollment: 400 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Lung Cancer
- Neoplasms, Lung
- Neoplasms, Pulmonary

## Interventions

- **DRUG:** talabostat
- **DRUG:** pemetrexed

## Key facts

- **NCT ID:** NCT00290017
- **Lead sponsor:** Point Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-02
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 400 (ESTIMATED)
- **Why stopped:** FDA Hold May 2007
- **Last updated:** 2007-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00290017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00290017, "Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy". Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/clinical/NCT00290017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*